Associate Director, US Real-World Evidence and Health Outcomes – Oncology Pipeline
GSK
6 months ago
Remote friendly (Durham, NC)
United States
Market Access
Responsibilities:
- Co-develop and maintain US real-world evidence (RWE) & health outcomes (HO) plans for 1–2 priority Oncology pipeline assets/indications; translate strategy into workplans, timelines, and resourcing; provide backup support across the portfolio.
- Own day-to-day leadership for assigned RWE/HEOR studies (e.g., RWE studies, cost-effectiveness/budget impact, burden of illness, treatment patterns, patient-focused outcomes), including design and execution with internal partners and external vendors.
- Support cross-functional evidence strategy forums/asset meetings by developing agendas/materials, surfacing options, documenting decisions, and tracking actions to closure.
- Draft/review project specifications, protocols, statistical analysis plans, study reports, abstracts, posters, and manuscripts; ensure SOP adherence and high scientific/operational quality.
- Provide input to Clinical Development on US-relevant trial design (patient population enrollment and endpoints/outcomes such as HRQoL, PROs, resource utilization, and other health outcomes).
- Provide RWE & HO input to internal development/commercialization decision-making (e.g., trial design considerations, data gap assessments, value messages, evidence prioritization/sequencing).
- Contribute ~20% effort to US RWE & HO strategy and execution for a marketed Oncology product in endometrial and rectal cancer, including lifecycle evidence needs and value communication.
- Maintain alignment with Field Based Payer Medical Teams and other field stakeholders to obtain customer insights and incorporate them into evidence plans/value communication.
- Manage vendors/contractors (scope, timelines, budget tracking, change control) and proactively escalate risks/issues.
- Complete required training, adhere to SOPs, and contribute to continuous improvement for efficient RWE/HO planning, execution, and dissemination.
Qualifications (Required):
- Master’s degree or PhD in health economics and outcomes research, epidemiology, public health, biostatistics, or related field.
- 1–3 years experience in pharmaceutical industry and/or managed care, hospital, academic, or healthcare consulting with HEOR/RWE strategy exposure.
- US payer/reimbursement and access environment know-how; familiarity with payer evidence needs for evidence planning/deliverables.
- Expertise in RWE and economic evaluation study designs/methods; experience with concept sheets/protocols, endpoints/data source selection, bias/confounding mitigation, and reviewing/authoring statistical analysis plans and study reports; ensure publication/disclosure readiness per SOPs/external requirements.
- Strong communication/presentation skills and ability to create decision-oriented materials for senior audiences.
- Proven ability to prioritize and manage multiple projects in a matrix environment.
Qualifications (Preferred):
- Success developing/executing health outcomes research plans and delivering high-quality data generation outputs.
- Oncology experience (US/global) and familiarity with evolving standards of care and stakeholder evidence needs.
- Masters + (4–6 years) or PhD (2–4+ years) experience in relevant industry/consulting settings, including collaboration with field-facing teams and/or Market Access.
- Experience managing real-world data sources/vendors (claims, EHR, registries) and translating findings into actionable insights/value messages.
- Ability to influence without authority; alignment of cross-functional stakeholders and driving actions to closure.
- Strategic execution experience translating evidence strategy into workplans and delivering across 1–2 concurrent asset workstreams.
- Project and vendor management experience (scope/success criteria, budget/timeline tracking, risk identification, mitigation via change control).
- Experience contributing to congress strategy and publication planning.
Application instructions:
- Apply and include how your experience in economic modeling and real-world evidence will support access and better outcomes for patients.
- Co-develop and maintain US real-world evidence (RWE) & health outcomes (HO) plans for 1–2 priority Oncology pipeline assets/indications; translate strategy into workplans, timelines, and resourcing; provide backup support across the portfolio.
- Own day-to-day leadership for assigned RWE/HEOR studies (e.g., RWE studies, cost-effectiveness/budget impact, burden of illness, treatment patterns, patient-focused outcomes), including design and execution with internal partners and external vendors.
- Support cross-functional evidence strategy forums/asset meetings by developing agendas/materials, surfacing options, documenting decisions, and tracking actions to closure.
- Draft/review project specifications, protocols, statistical analysis plans, study reports, abstracts, posters, and manuscripts; ensure SOP adherence and high scientific/operational quality.
- Provide input to Clinical Development on US-relevant trial design (patient population enrollment and endpoints/outcomes such as HRQoL, PROs, resource utilization, and other health outcomes).
- Provide RWE & HO input to internal development/commercialization decision-making (e.g., trial design considerations, data gap assessments, value messages, evidence prioritization/sequencing).
- Contribute ~20% effort to US RWE & HO strategy and execution for a marketed Oncology product in endometrial and rectal cancer, including lifecycle evidence needs and value communication.
- Maintain alignment with Field Based Payer Medical Teams and other field stakeholders to obtain customer insights and incorporate them into evidence plans/value communication.
- Manage vendors/contractors (scope, timelines, budget tracking, change control) and proactively escalate risks/issues.
- Complete required training, adhere to SOPs, and contribute to continuous improvement for efficient RWE/HO planning, execution, and dissemination.
Qualifications (Required):
- Master’s degree or PhD in health economics and outcomes research, epidemiology, public health, biostatistics, or related field.
- 1–3 years experience in pharmaceutical industry and/or managed care, hospital, academic, or healthcare consulting with HEOR/RWE strategy exposure.
- US payer/reimbursement and access environment know-how; familiarity with payer evidence needs for evidence planning/deliverables.
- Expertise in RWE and economic evaluation study designs/methods; experience with concept sheets/protocols, endpoints/data source selection, bias/confounding mitigation, and reviewing/authoring statistical analysis plans and study reports; ensure publication/disclosure readiness per SOPs/external requirements.
- Strong communication/presentation skills and ability to create decision-oriented materials for senior audiences.
- Proven ability to prioritize and manage multiple projects in a matrix environment.
Qualifications (Preferred):
- Success developing/executing health outcomes research plans and delivering high-quality data generation outputs.
- Oncology experience (US/global) and familiarity with evolving standards of care and stakeholder evidence needs.
- Masters + (4–6 years) or PhD (2–4+ years) experience in relevant industry/consulting settings, including collaboration with field-facing teams and/or Market Access.
- Experience managing real-world data sources/vendors (claims, EHR, registries) and translating findings into actionable insights/value messages.
- Ability to influence without authority; alignment of cross-functional stakeholders and driving actions to closure.
- Strategic execution experience translating evidence strategy into workplans and delivering across 1–2 concurrent asset workstreams.
- Project and vendor management experience (scope/success criteria, budget/timeline tracking, risk identification, mitigation via change control).
- Experience contributing to congress strategy and publication planning.
Application instructions:
- Apply and include how your experience in economic modeling and real-world evidence will support access and better outcomes for patients.